Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Biogen's FDA Approval Is Shocking

TheMotleyFool

0 0

Why Biogen's FDA Approval Is ShockingPhoto, wide shot, wide-angle lens, Specialty food store, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/7a8f69d5-c26e-46d9-b403-d3e5e9562eca.png

There hasn't been a new Alzheimer's drug in a couple of decades. Earlier this week the Food and Drug Administration (FDA) surprised the stock market when it gave a thumbs-up to Biogen's (NASDAQ: BIIB) new pharmaceutical, aducanumab, as a treatment for Alzheimer's. The trial data has convinced many doctors that the drug doesn't actually work -- and it has some safety issues as well. Nonetheless, Biogen stands to make billions of dollars off this drug.

What does the future hold for this stock? Corinne Cardina, bureau chief of Healthcare and Cannabis for the Motley Fool, and Fool.com writer Taylor Carmichael discuss Biogen. This Fool Live segment was recorded on June 18.

Source Fool.com

Like: 0

BIIB

Teilen